Type 2 Diabetes

At the recent American Diabetes Association annual meeting Lilly Diabetes had more than 60 disclosures discussing their latest work in the field. Of all that work the Mosaic study was arguably the biggest news to come out of New Orleans.

While it is not yet approved for the treatment of patients with type 1 diabetes recent studies on canagliflozin have shown it could be an option for this patient population.

The field of diabetes care is continually moving forward. Even as data was being presented at this year's meeting of the American Diabetes Association the future was at the forefront of many people's minds in an effort to help these patients even more.

There is no question that hunger can affect a person's life, a recent study looked at the scientific aspect of this discussion and what doctors can do to help patients with this challenge.

The obesity epidemic continues to grow in this country leaving the medical community to find new ways to help this patient population.

Is health-related quality of life as important as a patient’s A1c? Presentations at the 2016 ADA meeting discussed this component of diabetes care.

A fair amount of women who are diagnosed with gestational diabetes take active measures to lose weight – but what clinical outcomes does that have?

What happens when a patient with type 2 diabetes uses both a potassium (K)-sparing agent and sodium-glucose co-transporter 2 (SGLT2) inhibitor at the same time?

As adjunctive therapy with insulin in poorly controlled type 2 diabetes, which drugs proved more effective – SGLT2 inhibitors or DPP-4 inhibitors?

A network meta-analysis compared GLP-1 receptor agonists to traditional anti-diabetes drugs based on hypoglycemia incidence, HbA1c goals, and more.

Patients with diabetes face several challenges when it comes to coronary surgery success for numerous conditions. A recent study looked at the impact diabetes has on the success of coronary bypass grafts.

A new study may explain why nightshift works have a higher risk of type 2 diabetes.

Do patients diagnosed with anxiety disorder experience a greater burden of metabolic disorders such as diabetes and hyperlipidemia?

People with diabetes are 1.46 times more likely to lose their teeth than healthy patients.

Aflibercept exerts anti-angiogenic effects against galectin-1, a galactoside-binding lectin protein and novel angiogenic factor associated with proliferative diabetic retinopathy.

Exercise may lower the risk of diabetes, metabolic syndrome, or CV events, but the relationship between exercise and insulin sensitivity is complex.

Researchers compared four different methods of estimating starting basal insulin infusion rates when transitioning to pump therapy. Which was best?

There are many ways patients can better manage their cholesterol than they could just a few years ago. Whether they are successful in those efforts and the role of doctors and medications in that process remains to be seen.

Only a handful of medications carry an FDA indication for obesity, but metformin (which currently does not) has weighty evidence supporting its use.